2022/08/04
AcadeMab makes its mark at 2022 BIO USA
SAN DIEGO — AcadeMab participates in the 2022 BIO International Convention, the largest biotech industry exhibition in the world, and expands its business diligently.
The BIO International Convention is the world's largest annual biotech event, held in major cities in the United States. Around 1,140 companies opened their booths in the BIO USA 2022, with more than 15,000 people to visit from all over the world. The conference is the first to be held with in-person participation in three years due to the COVID-19 pandemic. This year's convention was held in San Diego, USA from June 13th to 16th. AcadeMab participated in an exhibition group jointly consisting of Taiwanese officials and industries and exhibited at the Taiwan Pavilion to introduce its new biological entities and the unique antibody developmentplatform for biotech research and development.
Since its establishment in 2020, AcadeMab has developed its own biological pipelines and technology platforms for antibody discovery and development. It has accumulated experience in novel antibodies development and seeks for potential partners for R&D collaboration or in- & out-licensing business. Its leading pipeline, AM-928, is moving forward in a fast path and will enter clinical stage in early 2023. Other than the pipeline development, reliable and high-qualityantibody discovery services to customers could also be provided with its unique technology platforms, including human scFv phage display and single B cell technology.
Through the intensive exposureand connection during this exhibition, AcadeMab will continue to contact many potential partners, show our in-depth knowledge and advantages, and establish global business opportunities.
The BIO International Convention is the world's largest annual biotech event, held in major cities in the United States. Around 1,140 companies opened their booths in the BIO USA 2022, with more than 15,000 people to visit from all over the world. The conference is the first to be held with in-person participation in three years due to the COVID-19 pandemic. This year's convention was held in San Diego, USA from June 13th to 16th. AcadeMab participated in an exhibition group jointly consisting of Taiwanese officials and industries and exhibited at the Taiwan Pavilion to introduce its new biological entities and the unique antibody developmentplatform for biotech research and development.
Since its establishment in 2020, AcadeMab has developed its own biological pipelines and technology platforms for antibody discovery and development. It has accumulated experience in novel antibodies development and seeks for potential partners for R&D collaboration or in- & out-licensing business. Its leading pipeline, AM-928, is moving forward in a fast path and will enter clinical stage in early 2023. Other than the pipeline development, reliable and high-qualityantibody discovery services to customers could also be provided with its unique technology platforms, including human scFv phage display and single B cell technology.
Through the intensive exposureand connection during this exhibition, AcadeMab will continue to contact many potential partners, show our in-depth knowledge and advantages, and establish global business opportunities.